Does Tranylcypromine Interact with Desvenlafaxine Succinate?
CDI records a contraindicated classification for Tranylcypromine and Desvenlafaxine Succinate. The stored summary is: Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI intended to treat psychiatric disorders or within 7 days of stopping desvenlafaxine. The mechanism involves inhibition of monoamine oxidase increases serotonin levels. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of monoamine oxidase increases serotonin levels
What To Tell Your Doctor or Pharmacist
If you are taking Tranylcypromine and your doctor is considering prescribing Desvenlafaxine Succinate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider